Contribution of IL-32 gene expression to viral persistence
IL-32 基因表达对病毒持久性的贡献
基本信息
- 批准号:10057016
- 负责人:
- 金额:$ 24.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-03 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntiviral AgentsAntiviral ResponseAvidityBiomedical EngineeringCardiac MyocytesCardiomyopathiesCell Culture TechniquesCell LineCell NucleusCellsChronicCollaborationsComplementary DNACoxsackie VirusesCoxsackievirus InfectionsCulture MediaCytolysisCytoplasmDevelopmentEpithelial CellsGene ExpressionGene Expression ProfilingGenesGenotypeGoalsGrantHela CellsHumanHuman poliovirusImmuneImmunityInfectionInflammationInnate Immune ResponseInterferon-alphaInterferon-betaInterferonsKnock-outKnowledgeMeasles virusMediator of activation proteinModelingMolecularNonlyticPathway interactionsPharmacologyPhenotypePopulationPredispositionProtein IsoformsProteomicsPublic HealthRNA VirusesRegimenSystemTherapeuticTimeToll-like receptorsUp-RegulationViralViral AntigensVirusVirus DiseasesVirus ReplicationWorkacute infectionbasechronic infectionexperimental studygene discoveryinduced pluripotent stem cellinhibitor/antagonistpathogenpersonalized medicineprogramsprophylacticresponsesensorsingle cell analysistranscriptome
项目摘要
Project Abstract
A case is being made for the utility of MeV persistence in development of lifelong immunity. The thought
is that persistent infection of epithelial cells, in addition to immune cells, may produce virus or viral
antigens to promote affinity maturation of antibodies for a sufficient duration of time that antibodies of
the highest avidity are produced. What governs establishment of a phenotype in an epithelial cell
conducive to establishment of a persistent infection is not known. However, such a cell should be able
to suppress but not eliminate virus multiplication, and virus release must occur by a non-lytic
mechanism to avoid a state of chronic inflammation. Establishing the existence of such persistent-
infection-competent epithelial cells and their gene expression, especially genes involved in control of
virus multiplication, is an essential first step in understanding the molecular basis of viral persistence.
Our single-cell analysis of poliovirus (PV) infection revealed a population of HeLa cells that were quite
proficient at supporting PV multiplication without lysis for as long as 36 h post-infection, which was the
duration of the experiment. We developed a strategy to isolate this sub-population of persistently-
infected cells using standard cell-culture approaches by adding an inhibitor of PV entry to the culture
media. We observed PV persistence for as long as six days post-infection, again the duration of the
experiment. Gene-expression analysis of these persistently-infected cells revealed a near-complete
suppression of sensors of viruses and other pathogens, including Toll-like receptors and “toll-free”
(cytosolic) receptors18. The gene for IL-32 was induced 7 fold (P-value <0.001). IL-32 has been
implicated in antiviral responses that are independent of type I and II interferons (IFNs); however,
effectors of the IL-32-dependent, antiviral pathway have yet to be discovered. The overarching goal of
the program that we will initiate under the auspices of this R21 grant is elucidation of genes, pathways,
and mechanisms required for viral persistence. The first goal of this application is to identify genes that
may contribute to establishment of persistence of CVB3 in human cardiomyocytes. The second goal of
this application is to inspire hypotheses for the mechanism of IL-32 action. These goals will be pursued
as indicated by the following aims: (1) Discover genes contributing to CVB3 persistence in human
cardiomyocytes; and (2) Discover effectors of the IL-32-dependent antiviral state in HeLa cells.
项目摘要
正在为MEV持久性在终身免疫力发展方面的效用而提出案例。想法
除了免疫细胞外,上皮细胞的持续感染还可能产生病毒或病毒
抗原促进抗体的亲和力成熟,以在足够的持续时间内
产生最高的亲和力。是什么控制上皮细胞中表型的建立
建立持续感染的导电尚不清楚。但是,这样的单元应该能够
要抑制但不能消除病毒繁殖,并且必须通过非散型发生病毒释放
避免慢性炎症状态的机制。建立这种持久的存在 -
感染竞争性上皮细胞及其基因表达,尤其是与控制的基因
病毒繁殖是理解病毒持久性分子基础的重要第一步。
我们对脊髓灰质炎病毒(PV)感染的单细胞分析表明,HELA细胞群体非常
感染后36小时,熟练支持PV繁殖,而无需裂解,这是
实验的持续时间。我们制定了隔离这种持续的亚群的策略 -
通过标准细胞培养方法感染细胞,通过将PV进入的抑制剂添加到培养物中
媒体。我们在感染后六天观察到PV持久性,再次持续
实验。对这些持续感染的细胞的基因表达分析显示出一个近乎完整的
抑制病毒和其他病原体的传感器,包括收费受体和“无电话”
(胞质)受体18。诱导IL-32的基因7倍(p值<0.001)。 IL-32已经
在独立于I型和II型干扰素(IFN)的抗病毒反应中实施;然而,
IL-32依赖性,抗病毒途径的效应因子尚未发现。总体目标
我们将在此R21赠款的主持下启动的程序是阐明基因,途径,
病毒持久性所需的机制。该应用程序的第一个目标是确定基因
可能有助于建立人类心肌细胞中CVB3的持久性。第二个目标
该应用是为了激发IL-32动作机制的假设。这些目标将被追求
如以下目的所示:(1)发现有助于人类CVB3持续存在的基因
心肌细胞; (2)发现IL-32依赖性抗病毒态在HELA细胞中的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRAIG E. CAMERON其他文献
CRAIG E. CAMERON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRAIG E. CAMERON', 18)}}的其他基金
Enteroviral 2C protein as a therapeutic target
肠道病毒2C蛋白作为治疗靶点
- 批准号:
10609524 - 财政年份:2022
- 资助金额:
$ 24.24万 - 项目类别:
Enteroviral 2C protein as a therapeutic target
肠道病毒2C蛋白作为治疗靶点
- 批准号:
10450381 - 财政年份:2022
- 资助金额:
$ 24.24万 - 项目类别:
Optimizing nucleoside analog efficacy with novel exonuclease inhibitors
使用新型核酸外切酶抑制剂优化核苷类似物的功效
- 批准号:
10514274 - 财政年份:2022
- 资助金额:
$ 24.24万 - 项目类别:
Contribution of IL-32 gene expression to viral persistence
IL-32 基因表达对病毒持久性的贡献
- 批准号:
10177863 - 财政年份:2020
- 资助金额:
$ 24.24万 - 项目类别:
相似国自然基金
人源化小鼠筛选猴痘抗体及机制研究
- 批准号:82373778
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
抗HTNV抗体mRNA修饰MSC在肾综合征出血热治疗中的作用研究
- 批准号:82302487
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人和小鼠中新冠病毒RBD的免疫原性表位及其互作抗体的表征和结构组学规律的比较研究
- 批准号:32371262
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
- 批准号:
10735492 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Broadly neutralizing SARS-CoV-2 peptidic knobs
广泛中和 SARS-CoV-2 肽旋钮
- 批准号:
10735902 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别:
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
用于鼻内预防和治疗冠状病毒的分子工程凝集素
- 批准号:
10629566 - 财政年份:2023
- 资助金额:
$ 24.24万 - 项目类别: